LT3919048T - Kasos vėžio gydymo būdai, panaudojant kompleksines terapijas, apimantys liposominį irinotekaną - Google Patents

Kasos vėžio gydymo būdai, panaudojant kompleksines terapijas, apimantys liposominį irinotekaną

Info

Publication number
LT3919048T
LT3919048T LTEP21171689.9T LT21171689T LT3919048T LT 3919048 T LT3919048 T LT 3919048T LT 21171689 T LT21171689 T LT 21171689T LT 3919048 T LT3919048 T LT 3919048T
Authority
LT
Lithuania
Prior art keywords
methods
pancreatic cancer
combination therapies
treating pancreatic
liposomal irinotecan
Prior art date
Application number
LTEP21171689.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Eliel Bayever
Navreet DHINDSA
Jonathan Basil Fitzgerald
Peter LAIVINS
Victor Moyo
Clet Niyikiza
Jaeyeon Kim
Original Assignee
Ipsen Biopharm Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3919048(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in New Jersey District Court litigation https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A24-cv-04991 Source: District Court Jurisdiction: New Jersey District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd. filed Critical Ipsen Biopharm Ltd.
Publication of LT3919048T publication Critical patent/LT3919048T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP21171689.9T 2012-06-13 2013-06-12 Kasos vėžio gydymo būdai, panaudojant kompleksines terapijas, apimantys liposominį irinotekaną LT3919048T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659211P 2012-06-13 2012-06-13
US201361784382P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
LT3919048T true LT3919048T (lt) 2026-03-25

Family

ID=48692681

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP21171689.9T LT3919048T (lt) 2012-06-13 2013-06-12 Kasos vėžio gydymo būdai, panaudojant kompleksines terapijas, apimantys liposominį irinotekaną

Country Status (26)

Country Link
US (10) US9452162B2 (enExample)
EP (4) EP3919048B1 (enExample)
JP (3) JP6310911B2 (enExample)
KR (3) KR101776808B1 (enExample)
CN (2) CN110051631A (enExample)
AU (3) AU2013202947B2 (enExample)
BR (1) BR112014031088A8 (enExample)
CA (1) CA2875824C (enExample)
DK (3) DK2861210T3 (enExample)
ES (2) ES2880089T3 (enExample)
FI (1) FI3919048T3 (enExample)
HR (1) HRP20260159T1 (enExample)
IL (3) IL294886A (enExample)
IN (1) IN2014DN11099A (enExample)
LT (1) LT3919048T (enExample)
MX (1) MX376937B (enExample)
NZ (1) NZ702469A (enExample)
PL (3) PL3266456T3 (enExample)
PT (3) PT3919048T (enExample)
RS (1) RS67811B1 (enExample)
RU (1) RU2663450C2 (enExample)
SI (3) SI2861210T1 (enExample)
SM (1) SMT202600126T1 (enExample)
TW (3) TWI729492B (enExample)
WO (1) WO2013188586A1 (enExample)
ZA (1) ZA201408804B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2015206667B2 (en) 2014-01-14 2020-05-14 Nektar Therapeutics Combination-based treatment method
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
AU2015360761B2 (en) * 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) * 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP2018527377A (ja) * 2015-09-16 2018-09-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌の処置におけるトポイソメラーゼ−ｉ阻害剤と免疫療法との組み合わせ
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
AU2017267449A1 (en) * 2016-05-18 2018-11-15 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
RU2761953C2 (ru) * 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
EP4087535A1 (en) 2020-01-10 2022-11-16 Tyndall Formulation Services, LLC Formulations of sn-38 with poly(amino acid) block polymers
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628659A (en) * 1951-01-17 1953-02-17 Charles R Carpenter Convertible furniture article
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
ATE341310T1 (de) 2000-02-04 2006-10-15 Lipoxen Technologies Ltd Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
JP4679028B2 (ja) 2000-05-15 2011-04-27 セルジーン コーポレイション 結腸直腸癌を治療するための組成物および方法
EP1299085B1 (en) 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005501840A (ja) 2001-07-23 2005-01-20 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト 癌の改良された治療のための手段および方法
US20030077833A1 (en) * 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (it) 2001-10-05 2003-04-05 Haworth S P A Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
CA2487425A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
NZ551748A (en) 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
RU2006146625A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1954286A2 (en) * 2005-11-10 2008-08-13 SmithKline Beecham Corporation Inhibitors of akt activity
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
SI2338487T1 (sl) 2006-01-17 2014-01-31 Abbott Laboratories Kombinacijska terapija z inhibitorji PARP
EP2004175A4 (en) 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
KR101153058B1 (ko) * 2006-11-30 2012-06-04 아크레이 가부시키가이샤 Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는 ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878229A (zh) * 2007-09-28 2010-11-03 巴塞尔大学医院 用于治疗癌症的免疫脂质体
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
MX2010010480A (es) 2008-03-25 2010-10-15 Schering Corp Metodos de tratamiento o prevencion del cancer colorrectal.
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2341908B1 (en) 2008-09-26 2016-04-13 Institut de Cancérologie de l'Ouest (I.C.O) Individual 5-fluorouracile dose optimization in folfiri treatment
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
PT2508170E (pt) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012012454A1 (en) 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
WO2012078695A2 (en) 2010-12-06 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
JP5947807B2 (ja) 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ ナノ粒子組成物への放射性核種の封入
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
MX336197B (es) 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) * 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
WO2013158803A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
US10111871B2 (en) 2013-08-27 2018-10-30 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
AU2015360761B2 (en) 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
AU2017267449A1 (en) 2016-05-18 2018-11-15 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)

Also Published As

Publication number Publication date
SI3919048T1 (sl) 2026-04-30
US20190117643A1 (en) 2019-04-25
AU2018201942A1 (en) 2018-04-12
AU2013202947A1 (en) 2014-01-16
SI3266456T1 (sl) 2022-03-31
JP2015523355A (ja) 2015-08-13
RS67811B1 (sr) 2026-03-31
IL235937A0 (en) 2015-01-29
IL235937B (en) 2022-08-01
IN2014DN11099A (enExample) 2015-09-25
TW201831168A (zh) 2018-09-01
JP2017149783A (ja) 2017-08-31
CN110051631A (zh) 2019-07-26
HK1248608A1 (en) 2018-10-19
KR20190107010A (ko) 2019-09-18
ES2880089T3 (es) 2021-11-23
PL2861210T3 (pl) 2017-12-29
DK3266456T3 (da) 2021-07-05
PL3266456T3 (pl) 2021-11-29
RU2018126616A (ru) 2019-03-12
PT3266456T (pt) 2021-07-28
EP2861210A1 (en) 2015-04-22
JP6857210B2 (ja) 2021-04-14
SI2861210T1 (sl) 2017-10-30
AU2018201942B2 (en) 2019-12-05
EP3266456B1 (en) 2021-05-05
EP4741019A2 (en) 2026-05-13
CA2875824C (en) 2021-05-18
RU2663450C2 (ru) 2018-08-06
US10980795B2 (en) 2021-04-20
FI3919048T3 (fi) 2026-03-13
BR112014031088A8 (pt) 2021-06-22
EP3919048B1 (en) 2026-01-28
EP3266456A1 (en) 2018-01-10
IL294886A (en) 2022-09-01
WO2013188586A1 (en) 2013-12-19
TWI729492B (zh) 2021-06-01
AU2013202947B2 (en) 2016-06-02
MX2014015391A (es) 2015-06-17
US20150328156A1 (en) 2015-11-19
TWI630924B (zh) 2018-08-01
TW202027727A (zh) 2020-08-01
US20170065578A1 (en) 2017-03-09
HK1209627A1 (en) 2016-04-08
US20160074382A1 (en) 2016-03-17
US20150374682A1 (en) 2015-12-31
RU2015100529A (ru) 2016-08-10
BR112014031088A2 (pt) 2017-06-27
JP2019116517A (ja) 2019-07-18
EP2861210B1 (en) 2017-05-03
NZ702469A (en) 2017-08-25
AU2013274287A1 (en) 2015-01-29
PT2861210T (pt) 2017-07-26
AU2013274287B2 (en) 2017-12-21
ZA201408804B (en) 2017-06-28
MX376937B (es) 2025-03-07
US9339497B2 (en) 2016-05-17
US20170368056A1 (en) 2017-12-28
EP4741019A3 (en) 2026-07-22
HRP20260159T1 (hr) 2026-03-27
KR20150021565A (ko) 2015-03-02
KR20170104638A (ko) 2017-09-15
EP3919048A1 (en) 2021-12-08
US9452162B2 (en) 2016-09-27
US20160228428A1 (en) 2016-08-11
CN104717961A (zh) 2015-06-17
US20150182521A1 (en) 2015-07-02
KR101776808B1 (ko) 2017-09-11
CA2875824A1 (en) 2013-12-19
ES2632915T3 (es) 2017-09-18
DK3919048T3 (da) 2026-02-09
TW201412345A (zh) 2014-04-01
US20220096458A1 (en) 2022-03-31
PL3919048T3 (pl) 2026-05-18
IL304631A (en) 2023-09-01
PT3919048T (pt) 2026-04-14
DK2861210T3 (en) 2017-07-24
SMT202600126T1 (it) 2026-05-12
US20240226090A1 (en) 2024-07-11
JP6310911B2 (ja) 2018-04-11
US9364473B2 (en) 2016-06-14
KR101997206B1 (ko) 2019-07-08
US9492442B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
ZA201408804B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IL288181A (en) Cancer treatment methods
IL272206A (en) Combined treatment for cancer
IL237791B (en) A method for treating cancer
SG11201503893RA (en) Method of treating cancer
ZA201205004B (en) Methods for treating pancreatic cancer
EP2575774A4 (en) COMBINATION THERAPY PROCEDURE FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL228644A0 (en) Cancer treatment methods
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
IL237569A0 (en) Means and method for treating solid tumors
SG11201502584XA (en) Peptides and methods for treating cancer
GB201220901D0 (en) CD44v6-derived peptides for treating pancreatic cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer
AU2012901918A0 (en) Methods for treating cancer
IL232266A0 (en) Cancer treatment methods
GB201202945D0 (en) Novel cancer therapies and methods
GB201108085D0 (en) Novel cancer therapies and methods